Accelerate Diagnostics reports Q3 2018 financial results
Nov 06, 2018
Revenue Placements up 40 Percent in U.S., Total Revenue up 64 Percent
TUCSON, Ariz., Nov. 6, 2018 /PRNewswire/ — Accelerate Diagnostics, Inc. today announced financial results for the quarter ending September 30, 2018. The company reported a 40% increase in U.S. instruments placed under commercial contract, and revenue for the quarter of $1.3 million, an increase of 64% from the prior year quarter. Worldwide, revenue-generating instruments combined with those under evaluation agreements grew to 458 instruments.
- Accelerate Diagnostics Expands Antimicrobials in New CE-Marked Accelerate PhenoTest™ BC kit
Aug 02, 2019
- Accelerate Diagnostics announces preliminary 2018 fourth quarter and full-year financial results
Jan 06, 2019